| Medical and Health Sciences | 2021-2025 | 229 | CN 22 | 99.96 |
| Biological Sciences | 2021-2025 | 602 | CN 210 | 99.36 |
| Cancer Research | Lifetime | 154 | CN 7 | 99.16 |
| Hepatology | Lifetime | 87 | CN 3 | 99.40 |
| Surgery | Lifetime | 855 | CN 10 | 99.19 |
| Oncology | Lifetime | 479 | CN 11 | 99.13 |
| Immunology | Lifetime | 918 | CN 28 | 96.85 |
| Biotechnology | Lifetime | 907 | CN 59 | 72.61 |
| Surgery | 2021-2025 | 63 | CN 2 | 99.63 |
| Cancer Research | 2021-2025 | 33 | CN 15 | 98.63 |
| Oncology | 2021-2025 | 176 | CN 20 | 98.65 |
| Hepatology | 2021-2025 | 55 | CN 6 | 98.54 |
| Molecular Biology | 2021-2025 | 433 | CN 183 | 97.86 |
| Epidemiology | 2021-2025 | 425 | CN 47 | 96.28 |
| Immunology | 2021-2025 | 259 | CN 61 | 93.73 |
| Pulmonary and Respiratory Medicine | 2021-2025 | 447 | CN 61 | 95.24 |
| Hepatocellular Carcinoma Treatment and Prognosis | Lifetime | 12 | CN 1 | 99.90 |
| Cholangiocarcinoma and Gallbladder Cancer Studies | Lifetime | 14 | CN 1 | 99.88 |
| Cancer Mechanisms and Therapy | Lifetime | 10 | CN 1 | 99.68 |
| Ferroptosis and cancer prognosis | Lifetime | 29 | CN 8 | 99.43 |
| Cancer-related molecular mechanisms research | Lifetime | 104 | CN 38 | 99.46 |
| MicroRNA in disease regulation | Lifetime | 109 | CN 33 | 99.44 |
| Cancer, Hypoxia, and Metabolism | Lifetime | 192 | CN 6 | 99.35 |
| Inflammatory Biomarkers in Disease Prognosis | Lifetime | 43 | CN 2 | 98.39 |
| Cancer Immunotherapy and Biomarkers | Lifetime | 272 | CN 10 | 99.33 |
| Immune cells in cancer | Lifetime | 192 | CN 19 | 98.80 |
| RNA modifications and cancer | Lifetime | 587 | CN 64 | 98.82 |
| Cancer, Lipids, and Metabolism | Lifetime | 242 | CN 4 | 98.97 |
| Cancer Research and Treatments | Lifetime | 251 | CN 16 | 98.38 |
| Circular RNAs in diseases | Lifetime | 208 | CN 112 | 98.42 |
| Peptidase Inhibition and Analysis | Lifetime | 354 | CN 8 | 98.63 |
| Liver Disease Diagnosis and Treatment | Lifetime | 887 | CN 34 | 98.93 |
| Extracellular vesicles in disease | Lifetime | 216 | CN 66 | 97.84 |
| Pancreatic and Hepatic Oncology Research | Lifetime | 532 | CN 8 | 98.73 |
| Cancer Genomics and Diagnostics | Lifetime | 769 | CN 15 | 98.63 |
| Hepatitis B Virus Studies | Lifetime | 633 | CN 35 | 98.36 |
| Liver physiology and pathology | Lifetime | 315 | CN 16 | 97.31 |
| Cancer Cells and Metastasis | Lifetime | 699 | CN 44 | 97.23 |
| Autophagy in Disease and Therapy | Lifetime | 576 | CN 89 | 96.48 |
| Chemokine receptors and signaling | Lifetime | 257 | CN 6 | 96.13 |
| Inflammation biomarkers and pathways | Lifetime | 963 | CN 169 | 68.22 |
| Cholangiocarcinoma and Gallbladder Cancer Studies | 2021-2025 | 4 | CN 1 | 99.89 |
| Hepatocellular Carcinoma Treatment and Prognosis | 2021-2025 | 20 | CN 4 | 99.63 |
| Cancer Mechanisms and Therapy | 2021-2025 | 6 | CN 3 | 99.44 |
| Cancer Genomics and Diagnostics | 2021-2025 | 173 | CN 7 | 98.69 |
| Peptidase Inhibition and Analysis | 2021-2025 | 59 | CN 11 | 98.55 |
| Cancer Immunotherapy and Biomarkers | 2021-2025 | 302 | CN 46 | 98.83 |
| Pancreatic and Hepatic Oncology Research | 2021-2025 | 200 | CN 19 | 98.09 |
| RNA modifications and cancer | 2021-2025 | 419 | CN 281 | 96.43 |
| Cancer-related molecular mechanisms research | 2021-2025 | 378 | CN 290 | 96.90 |
| Immune cells in cancer | 2021-2025 | 242 | CN 134 | 95.20 |
| Liver Disease Diagnosis and Treatment | 2021-2025 | 631 | CN 82 | 97.21 |
| Ferroptosis and cancer prognosis | 2021-2025 | 427 | CN 355 | 94.36 |
| Circular RNAs in diseases | 2021-2025 | 357 | CN 257 | 92.79 |
| Cancer, Hypoxia, and Metabolism | 2021-2025 | 801 | CN 354 | 87.58 |
| Colorectal Cancer Treatments and Studies | 2021-2025 | 969 | CN 140 | 89.06 |
| Single-cell and spatial transcriptomics | 2021-2025 | 897 | CN 239 | 86.19 |
| Liver physiology and pathology | 2021-2025 | 263 | CN 113 | 84.08 |
| Cancer, Lipids, and Metabolism | 2021-2025 | 972 | CN 404 | 83.57 |
| Inflammatory Biomarkers in Disease Prognosis | 2021-2025 | 619 | CN 264 | 78.12 |
| Macrophage Migration Inhibitory Factor | 2021-2025 | 171 | CN 48 | 65.21 |
